Hence, it was decided to undertake a second audit to compare this figure against all cases of PCMO detected in all clinics over a period of twelve months at QVH. Standard treatment at QVH for PCMO is ketrolac trometamol (Acular[R]) TDS for four weeks combined with dexamethasone 0.5% QDS for four weeks with a patient review at four to six weeks after treatment.
In the QVH audit all cases had OCT for confirmation of PCMO, including cases where visual acuity was better than 6/12 but cystic changes were observed.